about neoteryx

Exterior photo of Neoteryx corporate headquarters building

Our Mission

Neoteryx delivers on the promise of microsampling innovation. We are focused on delivering simple, quantitative microsampling solutions for biological samples, amenable to high throughput processing. Our customers work to advance pharmaceutical development, personalized medicine, biotechnology research and clinical research.

Who is Neoteryx? | Video

Our Technology 

Our Mitra® microsampler, is based on our patented VAMS® technology. It facilitates convenient, volumetric specimen collection and transportation of biological fluids to accelerate scientific breakthroughs, reduce costs, and enable new decentralized research models.

Our history

Incubated at Phenomenex for four years, the research and development of VAMS® technology occurred with the cooperation of global pharmaceutical companies. VAMS sampling simplifies the collection, storage, and transportation of biological specimens through the instrument known as the Mitra® Microsampling Device, commercially launched by Neoteryx in late 2016. Mitra devices accurately collect microliters of biological fluid in seconds. 

Photo of a mock-up prototype model of what would become the revolutionary DBS device the Mitra Microsampler


A chat over the limitations of Dried Blood Spot (DBS) cards between Dr. James Rudge (Phenomenex) and Dr. Neil Spooner (GlaxoSmithKline) reveals the market potential for a next generation dried matrix microsampling technology.

Interior image of 2 assembly workers at Neoteryx manufacturing facility.


10 µL devices based on VAMS® technology are thoroughly tested by five leading pharmaceutical organizations, validating that they collected a fixed, precise volume of biological fluid. 

CE and IVD symbols


As a CE-IVD registered device, Neoteryx is prepared to introduce the in vitro diagnostic European market to next generation dried blood collection and transportation.

Group of presenters at the London Microsampling workshop

Neoteryx expands into the United Kingdom to better serve its growing European customer base.

The Mitra Clamshell with 4 sampler tips.


The Mitra® microsampler is listed as an exempt medical device.

The Mitra Clamshell with 4 sampler tips in a laboratory setting

Responding to customer demand for a higher-volume specimen, Neoteryx releases 20 µL Mitra® microsamplers.

Interior of Neoteryx Building 2, manufacturing facility storage units

Manufacturing expands into a new building - Neo 2 - to better accommodate the growing need to manufacture more of this technology.

Collecting a blood drop from finger a finger prick in home setting


Mitra® devices gain wider acceptance through by some of the biggest names health, research, and medicine -  Charles River Labs, and Duke University to name a few.

close up of a 30 microliter tip


With the release of the 30 µL tips, users of Mitra® devices now collect more sample. This facilitates detection of analytes with low concentrations and multiplex analyses from one sampler tip.

Close up of 10 microliter tips collecting blood from a finger

Increasing awareness of the VAMS® advantage leads to a host of groundbreaking research. including breakthroughs in therapeutic drug monitoring and clinical trials. 

Exterior image of Neoteryx 3 building with Neoteryx logo
To accommodate an expanding team in Torrance, California, Neoteryx opens a new building, christened Neo 3.
Interior office shot of Neoteryx Netherlands


To further meet the needs of the European market, Neoteryx opens Neoteryx B.V. in Maastricht, the Netherlands.


At only five years old, VAMS® technology rides a wave of commercial and academic interest to rack up its 65th publication.

Close up image of a finger with a blood drop forming after its been punctured with a lancet

Increased use of remote specimen collection in health monitoring drives research with a focus on drug and alcohol testing.

Latest news